Ying Wang, Bangzhong Tang, Jing Xie, Xiaoqin Wang, Peng Ren, Guangmei Wu, Cuixia He, Minhui Zhu, Yue Su, Jiaxiang Ding, Yuanyuan Xu, Ling Fan, Qin Ge, Yuzhou Ding, Juan Zhu, Bingyan Liu, Rongfang Shan, Huan Zhou
PURPOSE: The study was aimed at evaluating the bioequivalence and safety of oseltamivir phosphate for suspension, provided by Shenzhen Beimei Pharmaceutical Co. Ltd. and manufactured by Hetero Labs Limited, and the reference product TAMIFLU® in healthy Chinese subjects. METHODS: A single-dose, randomized, two-phase, self-crossed model was adopted. Among 80 healthy subjects, 40 subjects in the fasting group and 40 subjects in the fed group. Subjects in the fasting group were randomized into two sequences according to the proportion of 1:1, each given 75 mg/12...
February 21, 2023: BMC Pharmacology & Toxicology